Long-term botulinum therapy for overactive bladder: myths and reality
- Authors: Kuzmin I.V.1, Slesarevskaya M.N.1, Amdiy R.E.1, Ulitko T.V.1, Al-Shukri S.K.1
-
Affiliations:
- Academician I.P. Pavlov First St. Petersburg State Medical University
- Issue: Vol 12, No 1 (2022)
- Pages: 71-84
- Section: Reviews
- URL: https://journals.rcsi.science/uroved/article/view/104335
- DOI: https://doi.org/10.17816/uroved104335
- ID: 104335
Cite item
Abstract
The review article presents data on the efficacy and tolerability of intravesical injections of botulinum toxin in patients with overactive bladder. The pharmacological bases of the use of botulinum therapy in this category of patients are described in detail. Data on the history of the use of botulinum toxin for medical purposes are presented. Experience to date shows that intravesical botulinum toxin injections are highly effective and well tolerated in patients with refractory overactive bladder. Botulinum therapy is included in domestic and foreign clinical guidelines as a 3rd line treatment for idiopathic and neurogenic overactive bladder. Indications for its implementation are the inefficiency and/or poor tolerability of oral pharmacotherapy. It is noted that the only botulinum toxin recommended for use in clinical practice for the treatment of overactive bladder is onabotulinumtoxin A (Botox®). The results of clinical studies are presented, showing that the effectiveness and safety of botulinum therapy do not decrease over time.
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Kuzmin
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN-code: 2684-4070
Scopus Author ID: 56878681300
https://www.1spbgmu.ru/ru/obrazovanie/kafedry/106-glavnaya/3828-igor-valentinovich-kuzmin
Dr. Sci. (Med.), Professor of the Department of Urology
Russian Federation, L‘va Tolstogo st., Saint Petersburg, 197022Margarita N. Slesarevskaya
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: mns-1971@yandex.ru
ORCID iD: 0000-0002-4911-6018
SPIN-code: 9602-7775
Scopus Author ID: 57196117211
https://www.1spbgmu.ru/ru/universitet/strustura/kafedry/106-glavnaya/3905-slesarevskaya-margarita-nikolaevna
Cand. Sci. (Med.), Senior Researcher, Research Center of Urology of the Research Institute of Surgery and Emergency Medicine
Russian Federation, L‘va Tolstogo st., Saint Petersburg, 197022Refat E. Amdiy
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: r.e.amdiy@mail.ru
ORCID iD: 0000-0003-1305-5791
SPIN-code: 2399-7041
Scopus Author ID: 6506347944
Dr. Sci. (Med.), Professor of the Department of Urology
Russian Federation, L‘va Tolstogo st., Saint Petersburg, 197022Tatiana V. Ulitko
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: ulitko-ta@yandex.ru
ORCID iD: 0000-0002-3521-8048
Senior Laboratory Assistant, Department of Clinical Anatomy and Operative Surgery named after prof. M.G. Prives
Russian Federation, L‘va Tolstogo st., Saint Petersburg, 197022Salman Kh. Al-Shukri
Academician I.P. Pavlov First St. Petersburg State Medical University
Author for correspondence.
Email: alshukri@mail.ru
ORCID iD: 0000-0002-4857-0542
SPIN-code: 2041-8837
Scopus Author ID: 6506423220
Doc. Sci. (Med.), Professor, Head of the Department of Urology
Russian Federation, L‘va Tolstogo st., Saint Petersburg, 197022References
- Abrams P, Cardozo L, Fall M, et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn. 2003;21(2):167–178. doi: 10.1002/nau.10052
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. doi: 10.1016/j.eururo.2006.09.019
- Kuzmin IV. Epidemiological aspects of overactive bladder and urge urinary incontinence. Urologicheskie vedomosti. 2015;5(3): 30–34. (In Russ.) doi: 10.17816/uroved5330-34
- Krivoborodov GG, Tur EI, Shirin DA. Hyperactive bladder the concept of disease and paradigms in the treatment. Medical Council. 2021;(4):121–126. (In Russ.) doi: 10.21518/2079-701X-2021-4-121-126
- Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St. Petersburg). 2021;11(3):241–256. (In Russ.) doi: 10.17816/uroved70710
- Al-Shukri SH, Kuzmin IV, Boriskin AG, et al. Correction of microcirculatory disorders in patients with overactive bladder. Nephrology (St. Petersburg). 2011;15(1):58–64. Cited: 2022 March 04 (In Russ.)
- Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000; 6(11 Suppl):S580–S590. Cited: 2022 March 09
- Al-Shukri SH, Kuzmin IV. Quality of life in patients with overactive bladder. Urologicheskie vedomosti. 2011;1(1):21–26. (In Russ.) Cited: 2022 March 04
- Kuzmin IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyrya [dissertation]. Saint Petersburg; 2007. 360 p. (In Russ.)
- Nederzhanie mochi. Klinicheskie rekomendatsii Minzdrava RF. 2020. Available from: https://cr.minzdrav.gov.ru/recomend/8
- Harding CK, Lapitan MC, Arlandis S. Non-neurogenic female LUTS. Guideline of European Urological Association. 2022. Available from: https://uroweb.org/guideline/non-neurogenic-female-luts
- Blok B, Castro-Diaz D, Del Popolo G, et al. Neuro-Urology / Guideline of European Urological Association. 2022. Available from: https://uroweb.org/guideline/neuro-urology
- Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5): 273–279. (In Russ.) doi: 10.32364/2587-6821-2021-5-5-273-279
- Romikh VV, Zakharchenko AV, Kukushkina LYu, et al. Current concepts of the overactive bladder in women. Strategy for choosing drug therapy. Obstetrics and Gynecology. 2021;(8):183–191. (In Russ.) doi: 10.18565/aig.2021.8.183-191
- Kuzmin IV, Al-Shukri SH. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology reports (St. Petersburg). 2020.10(2):163–171. (In Russ.) doi: 10.17816/uroved102163-171
- Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;(1):120–125 (In Russ.) doi: 10.18565/urology.2021.1.120-125
- Apostolidis A, Averbeck MA, Sahai A, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS2015). Neurourol Urodyn. 2017;36(4):882–893. doi: 10.1002/nau.23170
- Uvin P, Boudes M, Menigoz A, et al. Chronic administration of anticholinergics in rats induces a shift from muscarinic to purinergic transmission in the bladder wall. Eur Urol. 2013;64(3):502–510. doi: 10.1016/j.eururo.2013.05.031
- Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med. 2006;119(3 Suppl 1):9–15. doi: 10.1016/j.amjmed.2005.12.011
- Coupland CAC, Hill T, Dening T, et al Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084–1093. doi: 10.1001/jamainternmed.2019.0677
- Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: a beta-3 agonist for overactive bladder. Consult Pharm. 2014;29(12):823–837. doi: 10.4140/TCP.n.2014.823
- Whitcup SM. The History of Botulinum Toxins in Medicine: A Thousand Year Journey. Handb Exp Pharmacol. 2021;263:3–10. doi: 10.1007/164_2019_271
- Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins (Basel). 2021;13(1):58. doi: 10.3390/toxins13010058
- Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–922. doi: 10.1016/s0022-5347(17)42717-0
- Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–697. doi: 10.1097/00005392-200009010-00018
- Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–256. doi: 10.1016/j.eururo.2013.04.001
- Nitti VW, Dmochowski R, Herschorn S, et al. Onabotulinumtoxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–2193. doi: 10.1016/j.juro.2012.12.022
- Gong QQ, Xu YQ, Xu J, et al. Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder. Front Pharmacol. 2020;10:1618. doi: 10.3389/fphar.2019.01618
- Chohan N, Hilton P, Brown K, Dixon L. Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J. 2015;26(11):1605–1612. doi: 10.1007/s00192-015-2751-4
- Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–560. doi: 10.1016/j.eururo.2005.12.010
- Dan Spinu A, Gabriel Bratu O, Cristina Diaconu C, et al. Botulinum toxin in low urinary tract disorders – over 30 years of practice (Review). Exp Ther Med. 2020;20(1):117–120. doi: 10.3892/etm.2020.8664
- Krivoborodov GG, Vasiliev AV, Shumilo DV, et al. Botulinum toxin type A in patients with overactive bladder. Urologiya. 2010;(3):36–40. (In Russ.)
- Arkhireev AS, Romikh VV, Panteleyev VV, et al. The efficacy of therapy in patients with neurogenic and idiopathic detrusor hyperactivity depending on the dose of botulinum toxin type A. Experimental and Clinical Urology. 2017;(3):98–103. (In Russ.)
- Filippova ЕS, Bazhenov IV, Zyrjanov AV, et al. Clinical effectiveness of intradetrusor injections of botulinum toxin type a in dose 100 units in multiple sclerosis patients with neurogenic detrusor overactivity. Urology reports (St. Petersburg). 2020;10(1):25–32. (In Russ.) doi: 10.17816/uroved10125-32
- Al-Shukri SH, Kuzmin IV, Slesarevskaya MN, Ignashov YuA. Botulinum toxin type A in the treatment of bladder pain syndrome in women: initial results. Urologicheskie vedomosti. 2018;8(2):5–10. (In Russ.) doi: 10.17816/uroved825-10
- Nitti VW, Ginsberg D, Sievert KD, et al. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016;196(3):791–800. doi: 10.1016/j.juro.2016.03.146
- Rovner E, Kohan A, Chartier-Kastler E, et al. Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment. J Urol. 2016;196(3):801–808. doi: 10.1016/j.juro.2016.04.046
- Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010;184(6):2578–2585. doi: 10.1016/j.juro.2010.07.034
- Elbaset MA, Taha DE, El-Hefnawy AS, et al. Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial. Int Neurourol J. 2019;23(3):240–248. doi: 10.5213/inj.1938098.049
- Compérat E, Reitz A, Delcourt A, et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity – a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006;50:1058–1064. doi: 10.1016/j.eururo.2006.01.025
- Temeltas G, Tikiz C, Dagci T, et al. The effects of botulinum-A toxin on bladder function and histology in spinal cord injured rats: is there any difference between early and late application? J Urol. 2005;174:2393–2396. doi: 10.1097/01.ju.0000180410.78774.b5
- Pascali MP, Mosiello G, Boldrini R, et al. Effects of botulinum toxin type A in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections. J Urol. 2011;185(6 Suppl):2552–2557. doi: 10.1016/j.juro.2011.01.019
- Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol. 2008;53(6):1245–1253. doi: 10.1016/j.eururo.2008.02.037
- Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol. 2004;46(6): 784–791. doi: 10.1016/j.eururo.2004.07.011
- Fasano G, Grimaldi L, Nisi G, et al. The Regenerative Effects of Botulinum Toxin A: New Perspectives. J Invest Surg. 2022:1–2. doi: 10.1080/08941939.2021.2008553
- Vince R, Tracey A, Deebel NA, et al. Effects of vesical and perfusion pressure on perfusate flow, and flow on vesical pressure, in the isolated perfused working pig bladder reveal a potential mechanism for the regulation of detrusor compliance. Neurourol Urodyn. 2017;37(2):642–649. doi: 10.1002/nau.23362
- Jia C, Xing T, Shang Z, et al. Botulinum toxin A improves neurogenic bladder fibrosis by suppressing transforming growth factor β1 expression in rats. Transl Androl Urol. 2021;10(5):2000–2007. doi: 10.21037/tau-21-62
- Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center. Neurourol Urodyn. 2017;36(1):142–147. doi: 10.1002/nau.22892
- Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, et al. Onabotulinumtoxin A is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int Urogynecol J. 2021;32(1):65–74. doi: 10.1007/s00192-020-04423-0
- Bickhaus JA, Vaughan M, Truong T, et al. A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection. Int Urogynecol J. 2020;31(9):1907–1912. doi: 10.1007/s00192-020-04230-7
- Bickhaus JA, Bradley MS, Amundsen CL, et al. Does a Recent Urinary Tract Infection Increase the Risk of Postprocedure Urinary Tract Infection After Onabotulinum Toxin A? Female Pelvic Med Reconstr Surg. 2021;27(2):121–125. doi: 10.1097/SPV.0000000000000753
- Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–1813. doi: 10.1056/NEJMoa1208872
- Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA. 2016;316(13):1366–1374. doi: 10.1001/jama.2016.14617
- Herschorn S, Kohan A, Aliotta P, et al. The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin naïve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial. J Urol. 2017;198(1):167–175. doi: 10.1016/j.juro.2017.01.06
- Patel DN, Jamnagerwalla J, Houman J, et al. What is the true catheterization rate after intravesical onabotulinumtoxinA injection? Int Urogynecol J. 2018;29(7):1005–1009. doi: 10.1007/s00192-017-3440-2
- Marcelissen TA, Rahnama’i MS, Snijkers A, et al. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol. 2017;35(2): 307–311. doi: 10.1007/s00345-016-1862-y
- Osborn DJ, Kaufman MR, Mock S, et al. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675–678. doi: 10.1002/nau.22642
- Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017;28(6):845–850. doi: 10.1007/s00192-016-3212-4